Department of Rheumatology, Lille Catholic Hospitals, University of Lille, F-59160 Lomme, France.
EA 4490, PMOI, Physiopathologie des Maladies Osseuses Inflammatoires, University of Lille, F-59000, Lille, France.
Curr Pharm Des. 2018;24(6):684-689. doi: 10.2174/1381612824999180115103951.
Despite the fact that colchicine is by far the most ancient treatment for gout, new data are still being gathered. In gout, colchicine's ability to block polymerization of tubulin prevents the activation of the inflammasome. Efficacy of colchicine for the treatment of gout flares has been demonstrated only recently by a randomized- controlled trial, but it still has not been compared to other drugs. Use of colchicine is impaired by the impact of underlying comorbid conditions and drug interactions that can considerably modify its pharmacokinetics and pharmacodynamics. This manuscript reviews the state-of-the-art of colchicine in gout, from its known mechanisms of action to its effects, wanted and unwanted, expected and unexpected.
尽管秋水仙碱是目前为止治疗痛风最古老的药物，但仍在不断收集新的数据。在痛风中，秋水仙碱阻止微管蛋白聚合的能力可以阻止炎症小体的激活。秋水仙碱治疗痛风发作的疗效最近才通过一项随机对照试验得到证实，但它仍然没有与其他药物进行比较。秋水仙碱的使用受到潜在合并症和药物相互作用的影响，这些因素会极大地改变其药代动力学和药效学。本文综述了秋水仙碱在痛风中的最新研究进展，从其已知的作用机制到其预期和意外的效果。
